Global Blood Therapeutics Inc (NASDAQ:GBT) – Investment analysts at Oppenheimer increased their FY2020 EPS estimates for Global Blood Therapeutics in a research note issued to investors on Tuesday. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings per share of ($0.88) for the year, up from their previous estimate of ($1.72). Oppenheimer currently has a “Buy” rating and a $79.00 target price on the stock. Oppenheimer also issued estimates for Global Blood Therapeutics’ FY2021 earnings at $5.45 EPS.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the previous year, the company posted ($0.58) EPS.

Other equities analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Tuesday, October 10th. Needham & Company LLC assumed coverage on shares of Global Blood Therapeutics in a research note on Wednesday, September 20th. They issued a “buy” rating and a $51.00 target price for the company. SunTrust Banks raised their target price on shares of Global Blood Therapeutics to $67.00 and gave the company a “buy” rating in a research note on Monday, November 6th. BidaskClub upgraded shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 1st. Finally, J P Morgan Chase & Co restated a “buy” rating on shares of Global Blood Therapeutics in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $62.07.

Global Blood Therapeutics (GBT) traded down $3.15 during midday trading on Thursday, hitting $36.25. 3,989,862 shares of the stock were exchanged, compared to its average volume of 1,241,984. Global Blood Therapeutics has a 1 year low of $13.35 and a 1 year high of $45.85.

Several large investors have recently bought and sold shares of GBT. BNP Paribas Arbitrage SA raised its holdings in shares of Global Blood Therapeutics by 694.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock worth $124,000 after purchasing an additional 3,975 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Global Blood Therapeutics during the third quarter worth $200,000. Trexquant Investment LP purchased a new position in shares of Global Blood Therapeutics during the third quarter worth $202,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Global Blood Therapeutics during the third quarter worth $205,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Global Blood Therapeutics during the second quarter worth $211,000. Institutional investors and hedge funds own 90.48% of the company’s stock.

In other news, Director Charles J. Homcy sold 70,000 shares of Global Blood Therapeutics stock in a transaction on Friday, October 27th. The shares were sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares in the company, valued at $2,830,652.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Friday, September 29th. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now owns 140,055 shares of the company’s stock, valued at $4,201,650. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,500 shares of company stock valued at $3,003,350. 5.30% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/fy2020-eps-estimates-for-global-blood-therapeutics-inc-boosted-by-analyst-gbt/1768388.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.